



2024 China Dementia Conference: Research, prevention, diagnostics and treatment

Co-programmed by World Dementia Council

Shangri-La Hotel

Guangzhou, China

November 9-10, Sat-Sun, 2024

Outline

The high-level academic conference is for clinicians, academics and industry professionals working in China with international experts participating in the meeting. The conference will be live streamed. The World Dementia Council is helping programme the meeting.

Day 1

9 November

Time	Outline
08:00-09:00	Registration <i>Refreshments will be served</i>
09:00-10:00	Plenary one: welcome plenary <i>Welcome address from local and international representatives including an opening dance performance.</i> <ul style="list-style-type: none">• Introduction: Sen Liu• Welcome: Lenny Shallcross and Yuping Ning (10 minutes)• Opening speakers (introduced by Dr Yuping Ning)• Maria Carrillo (Chief Science Officer of the Alzheimer's Association)• Nancy Y. IP (President of Hong Kong University of Science and Technology)• Director of Guangzhou Municipal Health Commission• Xingcun Zhao (President of Guangzhou Medical University)• Vice Mayor of Guangzhou Municipal People's Government
10:00-10:30	Keynote one: dementia in China <i>Opening speaker will give an overview of the demographics of dementia in China, the research environment and treatment pathways.</i> Speaker: Jianping Jia introduced by Yuping Ning

10:30-11:00	Coffee break
11:00-11:30	<p>Keynote two: understanding disease, advances in research and understanding of different forms of dementia</p> <p><i>The session will consider global developments in understanding of disease mechanisms in Alzheimer's and other forms of dementia and reflect on research priorities in the decade ahead.</i></p> <p>Speaker: Colin Masters introduced by Maria Carrillo</p>
11:30-12:30	<p>Panel one: advances in research - Alzheimer's disease and other forms of dementia</p> <p><i>The session will pick up on the themes from the keynote address around understanding disease.</i></p> <p>Moderator: Maria Carrillo</p> <p>Panel: Colin Masters, Lawren Vandevrede, Dongsheng Fan, Dantao Peng, Mengchao Cui</p>
12:30-13:30	Lunch
13:30-14:30	<p>Keynote three: diagnosing Alzheimer's Disease</p> <p><i>The session will explore advances in diagnosing Alzheimer's Disease and others form of dementia from trials through to clinical settings.</i></p> <p>Speaker: Jing Gao and Charlotte Teunissen introduced by Jianping Jia</p>
14:30-15:30	<p>Panel two: diagnosing disease, developments in biomarkers in clinical practice</p> <p><i>The session will outline developments in biomarkers and what their use in clinical practice looks like in the future</i></p> <p>Moderator: Dongsheng Fan</p> <p>Panel: Yanjiang Wang, Charlotte Teunissen, Henrik Zetterberg, Amy Kit Yu FU, JianJun Jia, Tengfei Guo, Jun Xu</p>
15:30-16:00	Coffee break
16:00-17:00	<p>Panel three: Laboratory diagnostic quality control and future development of treatments</p> <p>Moderator: Charlotte Teunissen</p> <p>Panel: Charlotte Teunissen, Henrik Zetterberg, Nathalie Bastard, Jing Gao, Ling Qiu, Jun Liu, Yong Ji</p>
17:00-17:30	<p>Panel four: the decade ahead</p> <p>The session will consider what can be expected from the science bench through to the clinic in the decade ahead.</p> <p>Moderator: Maria Carrillo</p> <p>Panel: Henrik Zetterberg, Patrice Hugo, Yuping Ning, Yanjiang Wang, Zhengqi Lu</p>

Day 2

10 November

Time	Outline
09:00-09:30	Introduction and reflections Lenny Shallcross and Maria Carrillo
09:30-10:30	Panel five: Collecting real world evidence <i>The session will consider the collection of realworld evidence in an era of treatments and collaborations on the collection of data.</i> Moderator: Rebecca Edelmayer Panel: Colin Masters, Lawren Vandevrede, Patrice Hugo, Jinhe Li, Lu Shen, Qinyong Ye
10:30-11:00	Coffee break
11:00-12:00	Panel six: Developments beyond dementia. Research and treatments in psychiatric illnesses Moderator: Yuping Ning Panel: William Reichman, Karrin Anstey, Yuping Ning, Huali Wang, Xia Li, Shifu Xiao, Linda Chiuwa Lam
12:00-13:00	Lunch
13:00-14:00	Keynote four: preventing disease <i>The session will explore science of prevention and its implementation in practice.</i> Speakers: Yanjiang Wang and Karrin Anstey introduced by Linda Chiuwa Lam
14:00-15:00	Panel seven: lifestyle interventions in at risk population Moderator: Lenny Shallcross Panel: Maria Carrillo, Karrin Anstey, Wei Zhang, Jintai Yu, Gang Wang, Liyong Wu, Ying Su
15:00-15:30	Coffee break
15:30-16:30	Panel eight: Treatment of Dementia with Traditional Chinese Medicine (TCM) Moderator: Lenny Shallcross Panel: Karrin Anstey, Fanny C. F. IP, Nenggui Xu, Gang Chen, Wei Han, Jianwen Guo
16:30-17:00	Closing Plenary Speakers: Maria Carrillo, Lenny Shallcross, Colin Masters, Yuping Ning, Dongsheng Fan, Sen Liu

Biographies of speakers



As chief science officer, Maria C. Carrillo, Ph.D., sets the strategic vision for the Alzheimer’s Association global research program. Under her leadership, the Association is the world’s largest nonprofit funder of Alzheimer’s research — investing more than \$455 million since 1982 — and an internationally recognized pioneer in convening the dementia science community. Dr. Carrillo uses her platform as a noted public speaker to play an instrumental role in the Association’s efforts to lobby for increased funding for the disease. Dr. Carrillo oversees the implementation of the Association’s growing portfolio of research initiatives, including the Alzheimer’s Association International Conference® (AAIC®), the world’s largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer’s science and drug development. In addition, she leads the Association’s direct involvement in research by serving as a co-primary investigator for the Association-funded and led U.S. POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia. Dr. Carrillo earned her Ph.D. from Northwestern University’s Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer’s brain imaging and risk factors at Rush University Medical Center in Chicago.



Prof. Yuping Ning, MD, PhD, Secretary of the Party Committee of The Affiliated Brain Hospital of Guangzhou Medical University; Director of Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University
Dr Yuping Ning is the Secretary of the Party Committee of the Affiliated Brain Hospital of Guangzhou Medical University, the Director of Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University. She has long been involved in basic and clinical research on cognitive and emotional disorders in aging. She has won the first prize of China Medical Science and Technology Progress Award and the first prize of Science and Technology Progress Award of the Ministry of Education. In the past 5 years, she has presided over a number of national key research and development programs, National Natural Science Foundation projects, and 973 and 863 support programs of the Ministry of Science and Technology. She was awarded “Medical Leading Talents of Guangdong Province”, “March 8th Red Flag Bearer of Guangdong Province”, “High-level Health Key Talents of Guangzhou City”, “Excellent Dean of Guangdong Province”, and Outstanding scientific and Technological Worker in the field of Mental Health in China”.



Lenny Shallcross is **Executive Director** at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at the Department for Culture, Media and Sport and the Department of Health as well as working in Parliament and for the Labour Party.



Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and leads the UK DRI Fluid Biomarker Laboratory at UCL. His main research focus and clinical interest are fluid biomarkers for brain diseases, Alzheimer's disease in particular. He has published more than 1300 scientific articles and received numerous awards.



Charlotte Teunissen aims to improve patient for neurological diseases by body fluid biomarkers for diagnosis, stratification, prognosis and monitoring of treatment responses. Studies of her research group span the entire spectrum of biomarker development, from biomarker identification, using -omics methods, followed by assay development, analytical and clinical validation, and lastly implementation in clinical practice and trials.


Her young and dynamic lab has extensive expertise with state of the art technologies, such as various ultrasensitive and antibody-based assays, and vitro diagnostics for clinical routine lab analysis. She is responsible for the large biobank of the Amsterdam Dementia cohort, containing >10000 paired CSF and plasma/serum samples of individuals visiting the memory clinic of the Alzheimer Center Amsterdam. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers and the Body fluid Biomarkers PIA, and the recently founded Coral proteomics consortium. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers, and the JPND bPRIDE project, that aims to develop blood based biomarkers for early differential diagnoses of specific dementias.



Colin Louis Masters MD FAA AO is an Australian neuropathologist who researches Alzheimer's disease and other neurodegenerative disorders. He is laureate professor of pathology at the University of Melbourne. He has focused his career on research in Alzheimer's disease and other neurodegenerative diseases, including Creutzfeldt-Jakob disease. His work over the last 40 years is widely acknowledged as having had a major influence on Alzheimer's disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the A β amyloid protein which causes Alzheimer's disease. This work has led to the continued development of diagnostics and therapeutic strategies. More recently, his focus has been on describing the natural history of Alzheimer's disease as a necessary preparatory step for therapeutic disease modification. Professor Masters is currently a Laureate Professor at the University of Melbourne. He is also co-head of the Neurodegeneration Division of the Florey Institute, and a consultant at the Royal Melbourne Hospital. His achievements have been recognized by the receipt of many international awards.



Professor Nancy Y. IP is the President of The Hong Kong University of Science and Technology (HKUST) and the Morningside Professor of Life Science. Taking office in October 2022, she is the first female president of a publicly funded university in Hong Kong. She joined HKUST in 1993 and served as Head of Biochemistry, Dean of Science, and Vice-President for Research and Development. Ip is world-renowned for her significant contributions to the field of neuroscience. As a distinguished neuroscientist, she has been elected to various academies, including the Chinese Academy of Sciences, the US National Academy of Sciences, the American Academy of Arts and Sciences, the World Academy of Sciences, and the Hong Kong Academy of Science, and is a recipient of numerous awards and honors, including the National Natural Science Awards and the L'OREAL-UNESCO for Women in Science Award.




Dr. Dongsheng Fan is the Standing Committee Member of the Chinese Neurological Society, Professor of Neurology and Director of the Department of Neurology at Peking University Third Hospital. Main research interests include the study of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and the investigation of clinical phenotypes and genotypes differences in Chinese patient populations with cerebrovascular diseases.



Professor Jia Jianping is a senior neurologist. He reported the first family of AD in China, two new pathogenic genes and 13 new mutation sites, and pioneered the study of the genetic mechanism of AD in China. He discovered the mechanism of abnormal palmitoylation of AD and its intervention targets, expanding the idea of drug research.

The peripheral blood diagnostic markers he discovered advanced the early diagnosis of AD by 18 years. The results were published in the New England Journal (NEJM 2024). He reported the current situation of 15 million dementia in China and its risk factors, providing strategic consulting evidence for the construction of AD prevention and control system. His proof that a healthy lifestyle can reduce the risk of dementia in healthy elderly people by more than 50% and prove that dementia can be prevented was published in the British Medical Journal (BMJ 2023).


He has long served as the director of the Department of Neurology at Xuanwu Hospital, and once served as the chairman of Neurology at the Chinese Medical Association. He has published more than 740 papers, with a total of more than 40,000 citations, and has been selected as a global highly cited scholar for four consecutive years, among which 313 SCI papers have been published in NEJM, Lancet, BMJ and other journals. He won the second prize of National Science and Technology Progress. The International Alzheimer's Association awarded him the Zaven Scientific Achievement Award and praised him as "China's AD clinical research architect".



Dr. Jing Gao is a professor of Peking Union Medical College Hospital. Jing Gao is the deputy head of the Dementia and Cognitive Disorders Group and member of the Neuropathology Group of the Neurology Branch of the Chinese Medical Association, Standing Committee of the Neurology Branch of the Beijing Medical Association, head of the neuropathology Group, deputy head of the dementia and Cognitive Disorders Group, and invited to participate in a number of other dementia and degenerative diseases academic committees. Additionally, she serves on the editorial boards of the Chinese Journal of Neurology, the Chinese Medical Association BMJ Chinese Edition, and the Chinese Journal of Geriatric Multi-Organ Function. With over 30 years of clinical work in neurology, she specializes in leukoencephalopathy, cognitive impairment, dementia, non-tumor cranial neuropathology, and cerebrovascular diseases.



Dr. Yan-Jiang Wang, professor and director of Department of Neurology, Daping Hospital, Chongqing, China. He is a member of the Standing Committee of Neurology Branch of Chinese Medical Association and a member of Vas-Cog Asia. He is engaged in clinical diagnosis, treatment and scientific research of cognitive disorder-related diseases, revealing the systemic mechanism of Alzheimer's disease and exploring the transformation of diagnosis and treatment. As corresponding author, he has published more than 100 papers in Nat Rev Neurol, Lancet Infect Dis, JAMA Neurol, PNAS, Sci Adv, Nat Aging and other journals. He received the 20th Alzheimer's Award from Journal of Alzheimer's Disease.



Prof. Ling Qiu is the Deputy Director of Peking Union Medical College's Clinical Laboratory Diagnosis Department and the Clinical Laboratory Department. She is currently a member of the Biochemistry Group of Chinese Medical Association Laboratory Society and a member of the Standing Committee of Beijing Laboratory Society. Vice Chairman, Laboratory Medicine Branch, Chinese Geriatric Society; CNAS Laboratory Technical Committee, member of the Medical Professional Committee, ISO15189 accredited director reviewer; More than 10 social positions, such as member of the professional Committee of clinical inspection standards, health Standards Committee. Presided over or sub-projects presided over a total of 8 key support projects of the Ministry of Science and Technology, 863, 973, and the initial fund. As a PI in China, she undertook one of the IFCC global reference interval research projects. In the past five years, she has published 61 SCI papers (IF>160 points), 98 core journals and 42 Chinese series articles as the first author and corresponding author. She won the third prize of science and technology Progress in Sichuan Province and the second prize of science and technology progress in Henan Province, and 7 invention patents. Led more than 30 in vitro diagnostic product registration trials.



As vice president, Scientific Engagement, for the Alzheimer's Association, Rebecca M. Edelmayer, Ph.D., leads efforts to accelerate the organization's scientific agenda through the creation and delivery of ongoing research education. She engages with chapters across the country, ensuring that communities are informed of the global progress of dementia science and the organization's crucial role in advancing research to improve the lives of those facing Alzheimer's and all other dementia.

Dr. Edelmayer provides leadership on several of the Association's national and international initiatives in dementia science uniting researchers and clinicians on topics related to biomarker testing, drug discovery and therapeutic development. Dr. Edelmayer is a study investigator for the Association's Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), an initiative to gain insight on novel FDA-approved Alzheimer's therapies. She also serves on steering committees and as an external advisory board member for various cutting-edge scientific consortia established by the National Institute on Aging to advance treatment development, including the Accelerating Medicines Partnership-Alzheimer's Disease, MODEL-AD and TREAT-AD.

Dr. Edelmayer has more than 20 years of experience as a scientist and educator, spending more than six years as a pharmacologist in the Neuroscience and Immunology Divisions at Abbott and AbbVie. She has lectured, published and led collaborations in areas of neurodegenerative disease, neurophysiology and pain neurobiology. She completed her Ph.D. and postdoctoral training in medical pharmacology at the University of Arizona College of Medicine. Dr. Edelmayer holds a bachelor's degree in neuroscience from the University of Pittsburgh, where she also completed a National Institute of Mental Health research fellowship.



Professor Kaarin Anstey is an ARC Laureate Fellow is Director of the University of New South Wales Ageing Futures Institute in Sydney, Australia, and a conjoint Senior Principal Research Scientist at Neuroscience Research Australia. Her research focuses on improving brain health and dementia risk reduction through assessment, interventions, and policies. Anstey is a member of the World Dementia Council and is a member of the Governance Committee of the Global Council on Brain Health.



As an Assistant Professor of Neurology at UCSF, Dr. Lawren Vandevrede's overarching goal is to provide outstanding clinical care to patients with dementia and their caregivers. He completed his medical training in Chicago, where he also obtained a PhD degree in neuroscience working with his mentor to develop novel therapeutic agents for the treatment of [Alzheimer's disease](#). He completed his intern year in medicine at the Massachusetts General Hospital, his residency in neurology at Partners HealthCare in Boston, and his fellowship training at the UCSF Memory and Aging Center. His clinical and research interests are in advancing the care of patients with neurodegenerative disorders, either through development of novel therapeutics or increasing our understanding of the disease process



Dr. William E. Reichman is President and Chief Executive Officer of Baycrest, among the world's premier academic health care organizations focused on seniors' health and residential care and aging brain function.

Dr. Reichman has an appointment as Professor of Psychiatry on the Faculty of Medicine at the University of Toronto and is a recipient of an honorary degree of laws from OCAD University. He is a noted global authority on the delivery of innovative medical, mental health and dementia services in geriatric care settings.

Dr. Reichman is a former President of the International Psychogeriatric Association, the American Association for Geriatric Psychiatry, and the Geriatric Mental Health Foundation. He has been a special consultant to the Civil Rights Division of the United States Department of Justice on dementia and mental health-care delivery within nursing homes and has advised the WHO and the governments of Canada and China on health policy. He served as the weekly Senior Health columnist for the Star Ledger, New Jersey's highest circulation newspaper and has been widely interviewed and quoted by all of the major media outlets in the United States and Canada. Recently, he also served as Co-Chair of Canada's Ministerial Advisory Board on Dementia and was instrumental in the development of Canada's National Dementia Strategy.



Dr. Nathalie Bastard, PhD started her career as a Neuroscientist in academic research, totaling 40+ peer-reviewed publications. She obtained a PhD in Biomedical Sciences at the University of Antwerp, Belgium, in 2011, for her work around the application of CSF biomarkers to aid in the differential diagnosis of dementia. She was supported by a PhD fellowship from the L'Oréal-UNESCO "For Women in Science" program and the Fund for Scientific Research (FWO), and was awarded the McKinsey and Company scientific prize.

She joined Fujirebio Europe (formerly known as Innogenetics) in 2012 and currently holds the role of Strategic and Scientific Affairs Manager. Nathalie's experience is crucial for guiding the development of clinical evidence for Fujirebio's current biomarker portfolio and for evaluating evidence to expand existing indications for use. She also investigates new, innovative technologies and evaluates clinical utility and applicability for novel biomarkers in diagnostic areas of interest. She is responsible for developing the scientific publication strategy aimed to support product development, market access and regulatory submissions globally. She is an active and well-respected member of many local European and international consortia and projects (e.g. GBSC, AD-RIDDLE,...).



Dr. Patrice Hugo has more than 30 years of senior scientific leadership experience in laboratory operations, drug target and biomarker discovery & assay validation applied to drug development and diagnostics. He currently leads the scientific strategy and medical affairs and responsible for expanding laboratory testing to support clinical trials across therapeutic areas such as Oncology, Neurology (e.g. dementia) for the global Central Laboratories and specialty testing services including routine safety, Companion Diagnostics, Pathology, Genomics/ Genetics, Molecular, Vaccine, Flow Cytometry, Proteomics, Translational Science, Antibody library drug discovery, Bioanalytical PK, immunogenicity and ADME. In his prior appointment, Dr. Hugo was an Associate Vice President and Chief Clinical Trial Scientist at LabCorp/Covance. Dr. Hugo holds a Ph.D. in Experimental Medicine & Immunology at McGill University and held post-doctoral positions at the WEHI, Australia, and Howard Hughes Medical Institute, USA. He has published more than 75 scientific publications in internationally renowned journals and has been invited to speak at over 200 conferences.



Dr. Jinhe Li is the CEO of Shanghai Green Valley Pharmaceuticals and a Lefler Scholar at Harvard Medical School, while also serving as Director of the Joint Lab of Large-scale Intelligence Model of Neuromedicine at the Guangdong Institute of Intelligent Science and Technology. After receiving his Ph.D. in Biochemistry and Molecular Biology from the State University of New York, where he studied gene regulation, he completed his postdoctoral fellowship in Neurobiology at Harvard Medical School, focusing on Alzheimer's disease research. His career in pharmaceutical research includes roles as Principal Investigator at Pfizer, where he worked on discovering drug targets for Alzheimer's disease genes, and as Principal Investigator and Business Development Director at Abbott (now Abbvie), where he led the development of Alzheimer's disease therapies. A standing member of the National Institutes of Health (NIH) Review Panel for Alzheimer's disease and CNS disorders, Dr. Li is notably credited with the discovery of the Alzheimer's disease gene PS2 and its related gene Pen-2.



Xu Nenggui, MD, second-level professor, doctoral supervisor. Former Vice President of Guangzhou University of Traditional Chinese Medicine, member of the Science and Technology Commission of the Ministry of Education, member and Secretary-General of the 8th Chinese Medicine Discipline Evaluation Group of the State Council, Chief Scientist of the National 973 Program, Project Leader of the National Key R&D Program, Executive Vice President of Guangzhou Institute of Traditional Chinese Medicine, Chief Researcher of Guangdong Academy of Traditional Chinese Medicine, Director of South China Acupuncture Research Center of Guangzhou University of Chinese Medicine. The second “100 Outstanding Young Chinese Medicine” in China, the winner of the first Qihuang Scholar of the National Traditional Chinese Medicine Leader, the National Outstanding Scientific and Technological Worker, the training object of the “100 Outstanding Talents in Southern Guangdong” project in Guangdong Province, the winner of the Nanyue Innovation Award in Guangdong Province, the expert enjoying the special allowance of the State Council, the training object of the National Millions of Talents Project, the young and middle-aged expert with outstanding contributions to the country, and the honorary vice president of the Chinese Acupuncture and Moxibustion Association, the chairman of the Science and Technology Committee of the World Federation of Acupuncture and Moxibustion Societies, and the vice president of the Guangdong Acupuncture and Moxibustion Society.

The scientific research achievements presided over by him have won 1 second prize of the National Science and Technology Progress Award and 2 first prizes of the Science and Technology Progress Award of the Ministry of Education; The teaching achievements of the research have won 1 second prize of national teaching achievements and 1 first prize of Guangdong Provincial Teaching Achievement Award, and the research results have been published in the BMJ(IF=105.7), one of the four top medical journals in the world.



Dr Linda Lam is Clinical Professor at the Department of Psychiatry, the Chinese University of Hong Kong (CUHK).

She completed her medical undergraduate and doctoral degree at CUHK. She is the Past President of the Hong Kong College of Psychiatrists, past Chief Editor of the East Asian Archives of Psychiatry, and the founding President of the Chinese Dementia Research Association.

Her main research interests have been the epidemiology and impact of lifestyle and activity interventions on cognitive aging and dementia. She has also conducted the first territory wide epidemiological survey of mental disorders in Hong Kong, and pioneered lifestyle cognitive and physical exercise, and non-invasive brain stimulation interventions for Chinese older adults with neurocognitive disorders. She has published over 250 peer review articles in related research.

Dr Lam serves on the Editorial Boards of different psychiatric journals and is grant reviewer for the grant review boards in Hong Kong, the Alzheimer’s Association in the United States and Alzheimer’s society in United Kingdom. In 2017, she was awarded Honorary Fellowship of the Royal College of Psychiatrists at United Kingdom, and Honorary Membership of the World Psychiatric Association. In 2022, she was elected Honorary Fellow of the Hong Kong College of Psychiatrists



Dr. Fanny C. F. IP is the Chief Scientific Officer at the Hong Kong Center for Neurodegenerative Diseases (HKCeND), established by The Hong Kong University of Science and Technology (HKUST). Her early research focused on synapse formation and the potential benefits of traditional Chinese medicine for neurodegenerative disorders. Recently, she has led clinical studies on blood biomarkers for early detection of Alzheimer's disease. Dr. Ip has published 70 scientific papers, holds 35 granted patents, and has successfully licensed AD therapeutics for clinical development, commercializing technologies that benefit the community.



Professor Amy Kit Yu FU is a Research Professor in the Division of Life Science and Associate Director of the State Key Laboratory of Molecular Neuroscience at The Hong Kong University of Science and Technology. Her research focuses on discovering blood biomarkers for the early detection of Alzheimer's disease (AD) and elucidating the molecular and cellular mechanisms underlying the condition. She aims to identify therapeutic targets in the innate immune and blood systems through genetic association analysis. With over 90 articles published in peer-reviewed journals, Prof. Fu's findings have laid a strong foundation for developing new therapeutic strategies.



Professor Dantao Peng is the Director of the Department of Neurology and the Director of the Geriatrics Center of the China-Japan Friendship Hospital. She is also a member of the Standing Committee of the Geriatrics Branch of the Chinese Medical Association/Chinese Medical Doctor Association, the head of the Geriatric Neurology Group, a member of the Neurology Branch of the Chinese Medical Association/Chinese Medical Doctor Association, the chairman of the Anti-Aging Research Branch of the Chinese Geriatric Health Care Medical Research Association, and the vice chairman of the Vascular Cognitive Impairment Branch of the Chinese Stroke Society. She is the associate editor of the Chinese Journal of Neuroimmunology and Neurological Diseases, and a member of the editorial board of the Chinese Journal of Neurology and the Chinese Journal of Geriatrics. She has presided over 3 major projects of the Ministry of Science and Technology, 1 major project of the China Insurance Commission, 3 projects of the National Natural Science Foundation of China, 1 Capital Development Fund, and 1 project of the Beijing Municipal Science and Technology Commission.



Prof. Jianjun Jia, MD. Director of the Geriatric Medicine Institute of the PLA General Hospital, deputy director of the National Clinical Research Center for Geriatric Diseases of the PLA General Hospital, and chairman of the Academy of Cognitive Disorder of China of Chinese Geriatrics Society.

His main research focus and clinical interest are neuroimaging biomarkers for Alzheimer's disease. He has guided the compilation of eight expert consensus on cognitive impairment in China, and issued the Chinese version of Clinical Dementia Rating Scale (CDR). He has presided over a number of national key research and development programs, National Natural Science Foundation projects, and 863 support programs of the Ministry of Science and Technology. He received multiple rewards of brain PET imaging research in Alzheimer's.




Dr. Lu Shen is Chief Physician, Professor of Department of Neurology, Xiangya Hospital, Central South University, China.

Prof. Shen was awarded the Changjiang Distinguished Professorship by the Ministry of Education in 2021. She is currently the Director of the Neurology Department of Xiangya Hospital, Central South University and the Hunan Provincial Engineering Research Center for Cognitive Disorders. She is also the Deputy Director of the National Clinical Research Center for Geriatric Diseases (Xiangya Hospital). Her research focus on genetics and biomarkers of degenerative dementia, she has led one major project under the National Key R&D Program and nine projects under the National Natural Science Foundation of China. She published over 100 papers in the journal of Alzheimer & Dementia, Brain Behavior and Immunity, Advanced Science, Brain, AJHG, etc..



Dr. Qinyong Ye is a professor , doctoral supervisor and vice president of the Department of Neurology of the Union Hospital of Fujian Medical University, vice president of the Institute of Neuroscience of Fujian Medical University, and director of the Clinical Research Center for Precision Diagnosis and Treatment of Neurology Diseases in Fujian Province. He is also the vice president of the cognitive impairment branch of the Chinese Gerontological Association and the president of the neurology branch of the Fujian Medical Doctor Association. He is good at clinical and basic research on neurodegenerative diseases such as Parkinson's and movement disorders, Alzheimer's disease and cognitive impairment, and has presided over 1 key project supported by the National Natural Science Foundation of China Regional Innovation and Development Joint Fund, 4 general projects funded by the National Natural Science Foundation of China, and 1 sub-project of the National Science and Technology Support Program. He has published more than 50 SCI papers.



Dr. Zhengqi Lu is a Professor and Chairman at the Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University. His primary research focuses on cerebrovascular diseases, cognitive impairment in aging, and neuroimmune disorders. He serves as a grant reviewer for several scientific committees and medical associations.



Prof. Shifu Xiao is psychiatrist in chief of Mental Health Center affiliated to Shanghai Jiaotong University and Director of Alzheimer Disease and Related Disorders Center of Shanghai Jiaotong University. Vice Chair of Geriatrician Association of China, Consultant for the National Medical Products Administration of China. His research is focused on diagnosis and treatment of neurocognitive disorders and depression in the elderly. He , as leading PI, has conducted more than 10 phase II/III national multi-center, randomized, placebo-controlled clinical trials for anti-Alzheimer medications in the last decades. He has won several awards and honours, including the WHO-China Best Scientific Article Award for Neuroscience and Psychiatry, Science and Technology Award By the China Ministry of Education, Chinese Society of Medicine and Shanghai Government. Academic Achievement Award By State Council of China.



Dr. Yong Ji is a Chief Physician, Professor, and Doctoral Supervisor in the Department of Neurology at Beijing Tiantan Hospital, affiliated with Capital Medical University. He graduated from the Department of Medicine at China Medical University in 1987 and earned his M.D. in Neurology from Japan in 1999. In the same year, he began his postdoctoral fellowship at New York University Medical Center, where he also served as an Assistant Professor of Neurology. Dr. Li has an impressive academic record, having published over 100 papers, including more than 60 SCI-indexed papers. His specialties lie in the field of Neurology, with a particular focus on memory and dementia-related disorders.



Dr. Sen Liu, MD

Director, Pason Neuroscience Research Center

Chief Medical Officer, Beijing Pason Pharmaceuticals Inc.

Dr. Sen Liu has been working actively on the research projects of biomarkers for Alzheimer's disease diagnosis since 1998, and he has been responsible for organizing and coordinating multi-center clinical studies for diagnostic technology and new drug discovery. Currently, Dr. Liu's research focuses on the development of next generation of imaging tracers for the diagnosis of Alzheimer's disease and other neurodegenerative diseases.



Wei Zhang, MD, Ph. D. Postdoctor at the National Institutes of Health, Professor and Chief Physician of Neurology.

Dr. Wei Zhang is the director of the Center for Cognitive Neurology, Department of Neurology at Beijing Tiantan Hospital affiliated to Capital Medical University, Deputy Director of the Department of Geriatrics at Capital Medical University, and Director of the Department of Geriatrics at Beijing Tiantan Hospital.


Her main research areas are cognitive impairment and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as sleep disorders, mood disturbances, and movement disorders. She has led more than 20 research projects, sponsored more than 20 international and national clinical trials, and published near to 200 papers in the international and national journals. She holds important positions and deputy director in multiple international and national academic organizations, including Dementia and Cognitive Impairment Group of Neurology Section at Chinese Medical Association, Geriatrics Section at Chinese Medical Association, and Alzheimer's Disease Committee, etc.



Dr. Huali Wang is a Professor of Geriatric Psychiatry and the Director of Dementia Care and Research Center and Chair for Clinical Research Division at the Peking University Institute of Mental Health. Her research interest includes early diagnosis and management of mood and cognitive impairment in old age. Dr. Wang now leads the nationwide implementation of the NHC Dementia Care and Prevention Promotion Initiative.



Dr. Xia Li is director of Psychogeriatric Department, Shanghai Mental Health Center, Jiao Tong University School of Medicine. Dr. Li is the 5th Standing Committee Member of the Alzheimer's Disease Branch of the Chinese Geriatric Health Care Association and the Cognitive Impairment Branch of the Chinese Geriatrics Society. She specializes in the mood disorders and dementia in the elderly, as well as behavioral problem of Alzheimer's Disease.



Dr. Jun Xu is the deputy director, professor, chief physician and doctoral supervisor of the Department of Cognitive Disorders of Beijing Tiantan Hospital affiliated to Capital Medical University, and the leader of the Beijing Youth Top-notch Team, the vice president of the Cognitive Disorders Branch of the Chinese Geriatrics Society, the vice chairman of the Brain Health Branch of the Chinese Stroke Society, the chairman of the Brain Health Nutrition Committee of the Parenteral and Enteral Nutrition Branch of the Chinese Medical Association, and a member of the National Health Science Popularization Expert Database (2024). He is mainly engaged in basic and clinical research on Alzheimer's disease and related memory disorders in the direction of neuro-immune-nutritional metabolism, and has presided over 6 projects of the National Natural Science Foundation of China, 2 major chronic disease special projects of the Ministry of Science and Technology, and more than 20 provincial projects. He has published 56 SCI papers as the first or corresponding author, and has been authorized 5 invention patents and 23 software copyrights. 5 provincial and ministerial awards. He has published 3 monographs and participated in the editing/translation of 7 monographs.



Dr. Jin-Tai Yu is the Deputy Head of Department of Neurology in Huashan Hospital and the Vice Director of the Institute of Neurology, WHO Collaborating Center for Research and Training in Neurosciences, Fudan University, Shanghai, China. He also directs the Memory Disorders Subspecialty, National Center for Neurological Disorders in China, Huashan Hospital. Currently, he is focusing on basic and clinical research for Alzheimer's disease and related dementia, and the PI of several national grants on dementia, including Science and Technology Innovation 2030 Major Projects and National Natural Science Foundation of China. He has published more than 100 research papers in Nature Human Behaviour, Nature Aging, Lancet Neurology, Science Advances, Alzheimer's & Dementia, Nature communications, Nature Mental Health, et al. that have been cited more than 20000 times by peer scientists in the field. He is currently the Editor-in-Chief of Brain Disorders, Associate Editor-in-Chief of Annals of Translational Medicine, Senior Editor of Journal of Alzheimer's Disease.



Dr. Gang Wang is Professor, Attending neurologist, Chair of the Department of Neurology, Renji Hospital affiliated Medical School of Shanghai Jiao Tong University. He is also the vice chairman and secretary general of Neurodegenerative Disease Branch of the Chinese Neuroscience Society, vice Chairman of Alzheimer's Disease Branch of the Chinese Geriatric Health Care Association, and the committee member of cognitive impairment group in neurology branch for Chinese Medical Association, the academic committee of Chinese brain tissue bank collaboration alliance. He has long been engaged in Alzheimer's disease, Parkinson's disease and Functional neurological disorders. He is currently the associate editor of Journal of Alzheimer's disease, associate editor of Frontier in Aging Neuroscience, associate editor of Human Brain.



Dr. Liyong Wu is Professor and Vice Chair of the Department of Neurology, Xuanwu Hospital, Capital Medical University. His frontline research findings have been published in leading journals and has received numerous prestigious national and international awards. His research has focused on genetics, neuropsychology and neuroimaging of Alzheimer's disease, frontotemporal degeneration and prion disease. Professor Wu leads the establishment of the first national FTD multicenter cohort (CHIFGENS), systematically conducting research on the genetics and pathogenic mechanisms of familial FTD in China.



Dr. Mengchao Cui is a professor and doctoral supervisor at Beijing Normal University, and the director of the Key Laboratory of Radiopharmaceuticals of the Ministry of Education. Professor Cui Mengchao has long been engaged in the research and development of molecular probes targeting β -amyloid plaque ($A\beta$) and Tau protein aggregates in the brain of patients with Alzheimer's disease (AD), and a number of new drugs have been reviewed by ethics committees of many hospitals, and hundreds of human imaging studies have been completed, among which the positron emission tomography diagnostic drug targeting $A\beta$ [^{18}F]florbetazine has obtained the phase I clinical approval of a new drug in China.



Dr. Jianwen Guo is the professor of Guangdong Provincial Hospital of Traditional Chinese Medicine affiliated with Guangzhou University of Chinese Medicine. He is the discipline leader of “TCM Encephalopathy” in Guangzhou University of Chinese Medicine, the director of the Management Office of the State Key Laboratory of TCM, and the director of the major special Management Office of Guangdong Hospital of Traditional Chinese Medicine. He is mainly engaged in research and clinical work in the fields of TCM prevention and treatment of cerebrovascular diseases.



Dr. Gang Chen is the director of the Interdisciplinary Institute of Individualized Prevention and Treatment of Encephalopathy at Jinan University, the director of the Guangdong-Hong Kong-Macao Joint Laboratory of Brain-Peripheral Homeostasis and Health Regulation of Traditional Chinese Medicine, the deputy director of the Clinical and Translational Institute of Mental Disorders, and a professor at the College of Traditional Chinese Medicine. He received his Ph.D. in psychology from Rutgers University in United States and was awarded the title of Distinguished Professor of Jiangsu Province. He is engaged in the research of new advantages, new targets, targeted synergistic substances and their transformation in the personalized prevention and treatment of emotional and cognitive disorders in traditional Chinese medicine. The relevant results have been invited to report at more than 20 overseas conferences such as the United States Neuroscience Congress and the International Society of Behavioral and Neurogenetics (IBANGS) annual meeting, and more than 30 SCI papers of traditional Chinese medicine represented by rapid antidepressant research such as Yueju pills have been published. It has been approved to preside over more than 10 projects such as the National Key R&D Program. He is also the founding chairman of the Special Committee on Traditional Chinese Medicine and Brain Homeostasis Regulation of the Chinese Physiological Society, the chairman of the Guangzhou Association for the Promotion of Industry-University-Research in Encephalopathy Traditional Chinese Medicine, the executive director of the Basic Theory Branch of Traditional Chinese Medicine of the Chinese Association of Chinese Medicine, and the member committee member and chairman of the IBANGS Executive Committee.



Dr. Tengfei Guo completed training at the Technical University of Munich (PhD) and the University of California, Berkeley (Postdoc). He is the Assistant Professor at Peking University Shenzhen Graduate School and Shenzhen Bay Laboratory. He is primarily devoted to investigating early diagnosis and intervention in Alzheimer’s disease (AD) using multimodal PET and MRI imaging and novel CSF/plasma biomarkers. His findings have significantly impacted in understanding of pathological features, progression patterns, and clinical trials of AD.

He has received funding from the National Science Foundation of China for Excellent Young Scholars and the Guangdong Science Foundation for Distinguished Young Scholars. He also serves as an editor/reviewer for several international journals and has received multiple honors and awards.



Dr. Jun Liu is chief physician and professor of Neurology at the Second Affiliated Hospital of Guangzhou Medical University. He is vice director of the Neurology Research Institute at Guangzhou Medical University, director of the Neurology Department and head of the Cognitive Center at the Second Affiliated Hospital of Guangzhou Medical University.

From 1992 to 2002, he successively obtained his M.D. and Ph.D. degree from Sun Yatsen University of Medical Science. From 2006 to 2008, he got his post-doctoral training in the University of Kansas Medical Center. He has worked in the Sun Yat-sen Memorial hospital of Sun Yatsen University for 20 years and was transferred to the Second Affiliated Hospital of Guangzhou Medical University in 2022. His research field focus on the mechanisms and clinical research of Neurodegenerative disease. He got 6 National Natural Science Foundation of China as well as more than 20 provincial and ministerial projects. He published 75 papers in SCI journals. In 2019, he was awarded the title of “Top Ten Outstanding Young Neurologist” sponsored by Chinese Medical Doctor Association.



Dr. Wei Han is professor of the Department of Traditional Chinese Medicine, the Affiliated Brain Hospital of Guangzhou Medical University and Vice President of Guangdong Association of Acupuncture-Moxibustion. His research has focused on the prevention and treatment of psychosis with traditional Chinese medicine (acupuncture). He is skilled at combining unique acupuncture techniques such as “Tongdu Tiaoshen Acupuncture” with internal medicine prescriptions from Xin'an medicine to treat brain diseases and mental disorders, as well as other internal medical conditions.



Prof. Ying Su (MD,PhD) is Chief Physician in the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. In 2005-2006, she went to the University of Heidelberg for the doctoral research. She has long been engaged in clinical and basic research on cognitive impairment and neurodegenerative diseases. She has presided over a number of national, provincial and ministerial scientific research projects, and undertaken a number of clinical studies on Alzheimer's disease. She has extensive clinical experience in the diagnosis and treatment of memory and cognitive dysfunction.